Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab Study
Status:
Recruiting
Trial end date:
2029-01-17
Target enrollment:
Participant gender:
Summary
This is a multi-center multi-national rollover study to allow continued access to
crizanlizumab for patients with sickle cell disease (SCD) who are on crizanlizumab treatment
in a Novartis-sponsored study (parent study) and are benefiting from the treatment as judged
by the investigator.